Non-small cell lung cancer · line 1 · Ensartinib monotherapy (eXalt3) — ALK+ NSCLC, 1L metastatic
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-ENSARTINIB-ALK-1L-NSCLC |
| ID | IND-NSCLC-ALK-1L-ENSARTINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 1L alternative to alectinib for ALK+ metastatic NSCLC (eXalt3 registration). Existing IND-NSCLC-ALK-MET-1L (alectinib, Cat 1) remains standard-track default. eXalt3 source stub not yet in KB — citation flagged in commit body for source-ingest follow-up.
Used By
No reverse references found in the YAML corpus.